

Quantikine[®] ELISA

Human CA125/MUC16 Immunoassay

Catalog Number DCA125

For the quantitative determination of human Cancer Antigen 125 (CA125) concentrations in cell culture supernates, serum, plasma, saliva, urine, and human milk.

Note: The standard reconstitution method has changed. Read this package insert in its entirety before using this product.

This package insert must be read in its entirety before using this product.
For research use only. Not for use in diagnostic procedures.

TABLE OF CONTENTS

SECTION	PAGE
INTRODUCTION	1
PRINCIPLE OF THE ASSAY.....	2
LIMITATIONS OF THE PROCEDURE	2
TECHNICAL HINTS.....	2
MATERIALS PROVIDED & STORAGE CONDITIONS	3
OTHER SUPPLIES REQUIRED	3
PRECAUTIONS.....	4
SAMPLE COLLECTION & STORAGE.....	4
SAMPLE PREPARATION.....	4
REAGENT PREPARATION	5
ASSAY PROCEDURE	6
CALCULATION OF RESULTS.....	7
TYPICAL DATA.....	7
PRECISION	8
RECOVERY.....	8
LINEARITY.....	8
SENSITIVITY	9
CALIBRATION	9
SAMPLE VALUES.....	9
SPECIFICITY.....	10
REFERENCES.....	11
PLATE LAYOUT	12

MANUFACTURED AND DISTRIBUTED BY:

USA & Canada | R&D Systems, Inc.

614 McKinley Place NE, Minneapolis, MN 55413, USA
TEL: (800) 343-7475 (612) 379-2956 FAX: (612) 656-4400
E-MAIL: info@RnDSystems.com

DISTRIBUTED BY:

UK & Europe | R&D Systems Europe, Ltd.

19 Barton Lane, Abingdon Science Park, Abingdon OX14 3NB, UK
TEL: +44 (0)1235 529449 FAX: +44 (0)1235 533420
E-MAIL: info@RnDSystems.co.uk

China | R&D Systems China Co., Ltd.

24A1 Hua Min Empire Plaza, 726 West Yan An Road, Shanghai PRC 200050
TEL: +86 (21) 52380373 FAX: +86 (21) 52371001
E-MAIL: info@RnDSystemsChina.com.cn

INTRODUCTION

CA125 (cancer antigen 125) was named for an epitope on ovarian cancer cells, and now denotes the member of the mucin protein superfamily encoded by the MUC16 (mucin protein 16) gene (1-3). Expression of isoforms, proteolytic cleavage, and heavy N- and O-linked glycosylation produce type I transmembrane and secreted forms of human CA125 that can vary from 1148 to 22,152 amino acids (aa) in length and 200-5000 kDa in size (1-3).

Immunohistochemistry in the mouse demonstrates CA125 in normal epithelia lining the trachea, oral secretory glands, and olfactory gland, cochlear duct surface epithelia, stomach chief cells, mesothelia lining body cavities, and male and female reproductive organs (5). This expression pattern likely occurs also in humans (4). CA125 is cyclically expressed by the human endometrium and decidua (4). Its normal, low concentration in the serum or plasma can decrease post-menopause, but increase with advanced age (4). In the human eye, CA125 and other mucins protect the cornea and keep it hydrated (6, 7).

CA125 is notably overexpressed in ovarian cancers, but also in liver, pancreas, breast, lung, kidney, and other cancers (4, 8-11). Transmembrane CA125 can adhere to mesothelin in the peritoneum and other sites, facilitating invasion, migration, and metastasis of ovarian and pancreatic ductal cancers (11-14). CA125 binding to Galectin-1, Siglec-9, E-Selectin and L-Selectin has also been observed (15-17). CA125 adhesion to NK cells, thought to be mediated by Siglec-9, downregulates CD16, suppresses NK responses, and may promote immune evasion (17-21). CA125 may contribute to immune privilege during pregnancy by a similar mechanism (20, 21). Experimental downregulation of cancer cell CA125 expression inhibits tumor growth and increases apoptosis (22, 23).

In both cancerous and non-cancerous conditions, secreted CA125 in serum or plasma is positively associated with serosal fluid production in the presence of inflammatory cytokines such as TNF- α and IL-6 (24-30). Examples include ascites in the peritoneum and edema fluid surrounding the heart or lungs that is produced in the course of ovarian cancer, nephrotic syndrome, cardiac failure, liver diseases such as cirrhosis, lung cancer, or systemic lupus erythematosus (24-31). High levels of circulating CA125 often correlate with poor prognosis (8, 28-32).

The Quantikine[®] Human CA125/MUC16 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human CA125 in cell culture supernates, serum, plasma, saliva, urine, and human milk. It contains CHO cell-expressed recombinant human CA125 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human CA125 showed linear curves that were parallel to the standard curves obtained using the Quantikine[®] kit standards. These results indicate that this kit can be used to determine relative mass values for natural human CA125.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for human CA125 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any CA125 present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for human CA125 is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of CA125 bound in the initial step. The color development is stopped and the intensity of the color is measured.

LIMITATIONS OF THE PROCEDURE

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
- The kit should not be used beyond the expiration date on the kit label.
- Do not mix or substitute reagents with those from other lots or sources.
- If samples generate values higher than the highest standard, further dilute the samples with calibrator diluent and repeat the assay.
- Any variation in standard diluent, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.
- Variations in sample collection, processing, and storage may cause sample value differences.
- This assay is designed to eliminate interference by other factors present in biological samples. Until all factors have been tested in the Quantikine® Immunoassay, the possibility of interference cannot be excluded.

TECHNICAL HINTS

- When mixing or reconstituting protein solutions, always avoid foaming.
- To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer, and/or rotating the plate 180 degrees between wash steps may improve assay precision.
- Substrate Solution should remain colorless until added to the plate. Keep Substrate Solution protected from light. Substrate Solution should change from colorless to gradations of blue.
- Stop Solution should be added to the plate in the same order as the Substrate Solution. The color developed in the wells will turn from blue to yellow upon addition of the Stop Solution. Wells that are green in color indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution.

MATERIALS PROVIDED & STORAGE CONDITIONS

Store the unopened kit at 2-8 °C. Do not use past kit expiration date.

PART	PART #	DESCRIPTION	STORAGE OF OPENED/ RECONSTITUTED MATERIAL
Human CA125 Microplate	894275	96 well polystyrene microplate (12 strips of 8 wells) coated with a monoclonal antibody specific for human CA125.	Return unused wells to the foil pouch containing the desiccant pack. Reseal along entire edge of the zip-seal. May be stored for up to 1 month at 2-8 °C.*
Human CA125 Conjugate	894276	21 mL of a polyclonal antibody specific for human CA125 conjugated to horseradish peroxidase with preservatives.	May be stored for up to 1 month at 2-8 °C.*
Human CA125 Standard	894277	Recombinant human CA125 in a buffered protein base with preservatives; lyophilized. <i>Refer to the vial label for reconstitution volume.</i>	
Assay Diluent RD1X	895121	11 mL of a buffered protein base with preservatives. <i>May contain crystals. Warm to room temperature and mix well to dissolve.</i>	
Calibrator Diluent RD5P	895151	2 vials (21 mL/vial) of a buffered protein base with preservative.	
Wash Buffer Concentrate	895003	21 mL of a 25-fold concentrated solution of buffered surfactant with preservatives. <i>May turn yellow over time.</i>	
Color Reagent A	895000	12 mL of stabilized hydrogen peroxide.	
Color Reagent B	895001	12 mL of stabilized chromogen (tetramethylbenzidine).	
Stop Solution	895032	6 mL of 2 N sulfuric acid.	
Plate Sealers	N/A	4 adhesive strips.	

* Provided this is within the expiration date of the kit.

OTHER SUPPLIES REQUIRED

- Microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
- Pipettes and pipette tips.
- Deionized or distilled water.
- Squirt bottle, manifold dispenser, or automated microplate washer.
- 500 mL graduated cylinder.
- Horizontal orbital microplate shaker (0.12" orbit) capable of maintaining a speed of 500 ± 50 rpm.
- Test tubes for dilution of standards and samples.
- Human CA125 Controls (optional; R&D Systems®, Catalog # QC56).

PRECAUTIONS

High concentrations of CA125 are found in saliva. Take necessary precautions to protect kit reagents.

The Stop Solution provided with this kit is an acid solution.

Some components in this kit contain a preservative which may cause an allergic skin reaction. Avoid breathing mist.

Color Reagent B may cause skin, eye, and respiratory irritation. Avoid breathing fumes.

Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling. Refer to the MSDS on our website prior to use.

SAMPLE COLLECTION & STORAGE

The sample collection and storage conditions listed below are intended as general guidelines. Sample stability has not been evaluated.

Cell Culture Supernates - Remove particulates by centrifugation and assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Serum - Use a serum separator tube (SST) and allow samples to clot for 30 minutes at room temperature before centrifugation for 15 minutes at 1000 x g. Remove serum and assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Plasma - Collect plasma using heparin or EDTA as an anticoagulant. Centrifuge for 15 minutes at 1000 x g within 30 minutes of collection. Assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Note: *Citrate plasma has not been validated for use in this assay.*

Saliva - Collect saliva in a tube and centrifuge for 5 minutes at 10,000 x g. Collect the aqueous layer and assay immediately, or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Urine - Aseptically collect the first urine of the day (mid-stream), voided directly into a sterile container. Centrifuge to remove particulate matter, and assay immediately or aliquot and store at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

Human Milk - Centrifuge for 15 minutes at 1000 x g at 2-8 °C. Collect the aqueous fraction and centrifuge twice more for a total of 3 times. Assay immediately or aliquot and store samples at ≤ -20 °C. Avoid repeated freeze-thaw cycles.

SAMPLE PREPARATION

Serum and plasma samples require at least a 2-fold dilution. A suggested 2-fold dilution is 150 μ L of sample + 150 μ L of Calibrator Diluent RD5P.

Saliva samples require at least a 60-fold dilution. A suggested 60-fold dilution is 10 μ L of sample + 590 μ L of Calibrator Diluent RD5P.

Human milk samples require at least a 40-fold dilution. A suggested 40-fold dilution is 10 μ L of sample + 390 μ L of Calibrator Diluent RD5P.

REAGENT PREPARATION

Bring all reagents to room temperature before use.


Note: High concentrations of CA125 are found in saliva. Take necessary precautions to protect kit reagents.

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 20 mL of Wash Buffer Concentrate to deionized or distilled water to prepare 500 mL of Wash Buffer.

Substrate Solution - Color Reagents A and B should be mixed together in equal volumes within 15 minutes of use. Protect from light. 200 μ L of the resultant mixture is required per well.

Human CA125 Standard - Refer to the vial label for reconstitution volume. Reconstitute the Human CA125 Standard with deionized or distilled water. This reconstitution produces a stock solution of 320 U/mL. Mix the standard to ensure complete reconstitution and allow the standard to sit for a minimum of 15 minutes. Mix well prior to making dilutions.

Pipette 900 μ L of Calibrator Diluent RD5P into the 32 U/mL tube. Pipette 500 μ L into the remaining tubes. Use the stock solution to produce a dilution series (below). Mix each tube thoroughly before the next transfer. The 32 U/mL standard serves as the high standard. Calibrator Diluent RD5P serves as the zero standard (0 U/mL).



ASSAY PROCEDURE

Bring all reagents and samples to room temperature before use. It is recommended that all standards, samples, and controls be assayed in duplicate.

Note: *High concentrations of CA125 are found in saliva. Take necessary precautions to protect kit reagents.*

1. Prepare all reagents, working standards, and samples as directed in the previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
3. Add 100 μ L of Assay Diluent RD1X to each well. *Assay Diluent RD1X may contain crystals. Warm to room temperature and mix well to dissolve before use.*
4. Add 100 μ L of standard, control, or sample* per well. Cover with the adhesive strip provided. Incubate for 2 hours at room temperature on a horizontal orbital microplate shaker (0.12" orbit) set at 500 ± 50 rpm. A plate layout is provided to record standards and samples assayed.
5. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (400 μ L) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
6. Add 200 μ L of Human CA125 Conjugate to each well. Cover with a new adhesive strip. Incubate for 2 hours at room temperature on the shaker.
7. Repeat the aspiration/wash as in step 5.
8. Add 200 μ L of Substrate Solution to each well. Incubate for 30 minutes at room temperature **on the benchtop. Protect from light.**
9. Add 50 μ L of Stop Solution to each well. The color in the wells should change from blue to yellow. If the color in the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.
10. Determine the optical density of each well within 30 minutes, using a microplate reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

*Samples may require dilution. See Sample Preparation section.

CALCULATION OF RESULTS


Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density (O.D.).

Create a standard curve by reducing the data using computer software capable of generating a log/log curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on a log/log graph. The data may be linearized by plotting the log of the human CA125 concentrations versus the log of the O.D. on a linear scale, and the best fit line can be determined by regression analysis.

If the samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

TYPICAL DATA

This standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.



(U/mL)	O.D.	Average	Corrected
0	0.013 0.013	0.013	—
0.5	0.063 0.064	0.064	0.051
1	0.106 0.115	0.111	0.098
2	0.214 0.218	0.216	0.203
4	0.374 0.414	0.394	0.381
8	0.760 0.765	0.763	0.750
16	1.400 1.423	1.412	1.399
32	2.480 2.503	2.492	2.479

PRECISION

Intra-assay Precision (Precision within an assay)

Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays)

Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.

Sample	Intra-Assay Precision			Inter-Assay Precision		
	1	2	3	1	2	3
n	20	20	20	20	20	20
Mean (U/mL)	4.26	10.0	19.0	4.22	9.74	18.7
Standard deviation	0.066	0.101	0.266	0.313	0.527	0.666
CV (%)	1.5	1.0	1.4	7.4	5.4	3.6

RECOVERY

The recovery of human CA125 spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type	Average % Recovery	Range
Cell culture media (n=4)	99	95-102%
Serum* (n=4)	97	90-101%
EDTA plasma* (n=4)	97	93-101%
Heparin plasma* (n=4)	97	92-100%

*Samples were diluted prior to assay.

LINEARITY

To assess the linearity of the assay, samples containing high concentrations of human CA125 were serially diluted with calibrator diluent to produce samples with values within the dynamic range of the assay.

		Cell culture supernates* (n=4)	Serum* (n=4)	EDTA plasma* (n=4)	Heparin plasma* (n=4)	Saliva* (n=4)	Urine (n=4)	Human milk* (n=4)
1:2	Average % of Expected	107	109	107	107	105	104	105
	Range (%)	103-109	107-112	106-108	104-110	103-108	103-106	102-107
1:4	Average % of Expected	107	112	110	110	105	102	106
	Range (%)	102-109	108-115	107-113	106-114	103-108	97-106	102-108
1:8	Average % of Expected	104	111	110	110	102	100	103
	Range (%)	97-107	106-116	106-112	107-114	100-105	98-102	99-107
1:16	Average % of Expected	100	107	108	108	98	—	99
	Range (%)	93-104	102-112	104-113	104-110	95-102	—	92-104

*Samples were diluted prior to assay.

SENSITIVITY

Twenty-six assays were evaluated and the minimum detectable dose (MDD) of human CA125 ranged from 0.007-0.099 U/mL. The mean MDD was 0.035 U/mL.

The MDD was determined by adding two standard deviations to the mean O.D. value of twenty zero standard replicates and calculating the corresponding concentration.

CALIBRATION

This immunoassay is calibrated against a highly purified CHO cell-expressed recombinant human CA125/MUC16 produced at R&D Systems®. Unit values were assigned by methods outlined in Klug, T.L. *et al.* (1984) *Cancer Res.* **44**:1048.

SAMPLE VALUES

Serum/Plasma/Saliva/Urine/Human Milk - Samples from apparently healthy volunteers were evaluated for the presence of human CA125 in this assay. No medical histories were available for the donors used in this study.

Sample Type	Mean (U/mL)	Range (U/mL)	Standard Deviation (U/mL)
Serum (n=36)	8.95	1.81-34.8	7.32
EDTA plasma (n=36)	8.54	1.72-32.1	6.84
Heparin plasma (n=36)	8.52	1.70-32.9	6.92
Human milk (n=18)	234	35.7-1071	252
Saliva (n=10)	396	64.6-1073	312

Sample Type	Mean of Detectable (U/mL)	% Detectable	Range (U/mL)
Urine (n=12)	5.97	42	ND-17.4

ND=Non-detectable

Cell Culture Supernates - OVCAR-3 human ovarian carcinoma cells were cultured in RPMI and supplemented with 20% fetal bovine serum, 10 µg/mL bovine insulin, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, and 1.5 g/L sodium bicarbonate until confluent. An aliquot of the cell culture supernate was removed, assayed for human CA125, and measured 1565 U/mL.

SPECIFICITY

This assay recognizes natural and recombinant human CA125.

The factors listed below were prepared at 50 ng/mL in calibrator diluent and assayed for cross-reactivity. Preparations of the following factors at 50 ng/mL in a mid-range recombinant human CA125 control were assayed for interference. No significant cross-reactivity or interference was observed.

Recombinant human:

CD300LG/Nepmucin
E-Cadherin
Endomucin
Galectin-1
Galectin-3
Mesothelin
MMR/CD206
MUC-1
MUC-4
MUC-20
MUCDHL

Recombinant mouse:

CD300LG/Nepmucin
Galectin-1
Galectin-3
E-Cadherin
Endomucin
MMR/CD206
MUC-20
MUCDHL

REFERENCES

1. Bast, R.C. *et al.* (1981) *J. Clin. Invest.* **68**:1331.
2. Yin, B.W.T. and K.O. Lloyd (2001) *J. Biol. Chem.* **276**:27371.
3. Yin, B.W.T. *et al.* (2002) *Int. J. Cancer* **98**:737.
4. Sikaris, K.A. (2011) *Heart Lung Circ.* **20**:634.
5. Wang, Y. *et al.* (2008) *Differentiation* **76**:1081.
6. Blalock, T.D. *et al.* (2007) *Invest. Ophthalmol. Vis. Sci.* **48**:4509.
7. Mantelli, F. and P. Argueso (2008) *Curr. Opin. Allergy Clin. Immunol.* **8**:477.
8. Haridas, D. *et al.* (2011) *PLoS ONE* **6**:e26839.
9. Higashi, M. *et al.* (2012) *Pathobiology* **79**:101.
10. Hoshino, M. *et al.* (2010) *J. Cancer Res. Clin. Oncol.* **136**:457.
11. Kaneko, O. *et al.* (2009) *J. Biol. Chem.* **284**:3739.
12. Rump, A. *et al.* (2004) *J. Biol. Chem.* **279**:9190.
13. Shimizu, A. *et al.* (2012) *Cancer Sci.* **103**:739.
14. Gubbels, J.A.A. *et al.* (2006) *Mol. Cancer* **5**:50.
15. Seelenmeyer, C. *et al.* (2003) *J. Cell Sci.* **116**:1305.
16. Chen, S.H. *et al.* (2012) *FASEB J.* **26**:1349.
17. Belisle, J.A. *et al.* (2010) *Mol. Cancer* **9**:118.
18. Patankar, M.S. *et al.* (2005) *Gynecol. Oncol.* **99**:704.
19. Gubbels, J.A.A. *et al.* (2010) *Mol. Cancer* **9**:11.
20. Belisle, J.A. *et al.* (2007) *Immunology* **122**:418.
21. Tyler, C. *et al.* (2012) *Am. J. Reprod. Immunol.* **68**:28.
22. Reinartz, S. *et al.* (2012) *Eur. J. Cancer* **48**:1558.
23. Lakshmanan, I. *et al.* (2012) *Oncogene* **31**:805.
24. Topalak, O. *et al.* (2002) *Gynecol. Oncol.* **85**:108.
25. Yang, Z. *et al.* (2012) *Clin. Exp. Rheumatol.* **30**:93.
26. Peng, T. *et al.* (2012) *Clin. Lab.* **58**:113.
27. Huang, F. *et al.* (2012) *Med. Hypotheses* **79**:381.
28. D'Aloia, A. *et al.* (2003) *J. Am. Coll. Cardiol.* **41**:1805.
29. Kouris, N.T. *et al.* (2006) *Hellenic J. Cardiol.* **47**:269.
30. Kosar, F. *et al.* (2006) *Eur. J. Heart Fail.* **8**:270.
31. Karaca, O. *et al.* (2012) *Congest. Heart Fail.* **18**:144.
32. Prochazka, V. *et al.* (2012) *Int. J. Hematol.* **96**:58.

PLATE LAYOUT

Use this plate layout to record standards and samples assayed.

12									
11									
10									
9									
8									
7									
6									
5									
4									
3									
2									
1									
	A	B	C	D	E	F	G	H	

NOTES

NOTES

All trademarks and registered trademarks are the property of their respective owners.

©2017 R&D Systems®, Inc.